This Amendment No.\u00a03 (this \u201cAmendment\u201d) amends and supplements the Tender Offer
\nStatement on Schedule TO (together with any amendments and supplements thereto, including this Amendment, the \u201cSchedule TO\u201d) filed by (i)\u00a0GSK plc, a public limited company organized under the laws of England and Wales
\n(\u201cUltimate Parent\u201d), (ii) GlaxoSmithKline LLC, a Delaware limited liability company and an indirect wholly-owned subsidiary of Ultimate Parent (\u201cParent\u201d), and (iii)\u00a0Harmony Row Acquisition Co., a Delaware
\ncorporation (\u201cPurchaser\u201d) and a direct wholly-owned subsidiary of Parent. The Schedule TO relates to the offer by Purchaser to purchase all of the issued and outstanding shares of the Class\u00a0A Common Stock, par value $0.0001
\nper share (the \u201cClass\u00a0A Shares\u201d), and Class\u00a0B Common Stock, par value $0.0001 per share (the \u201cClass\u00a0B Shares\u201d and, together with the Class\u00a0A Shares, the
\n\u201cShares\u201d), of Nuvalent, Inc., a Delaware corporation (the \u201cCompany\u201d), for $124.00 per Share, net to the seller in cash, without interest (such consideration as it may be increased from time to time pursuant to
\nthe terms of the Merger Agreement (as defined below), the \u201cOffer Price\u201d), subject to any applicable withholding taxes, and upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June\u00a024, 2026
\n(together with any amendments or supplements thereto, the \u201cOffer to Purchase\u201d) and in the accompanying letter of transmittal (together with any amendments or supplements thereto, the \u201cLetter of Transmittal\u201d
\nwhich, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, collectively constitute the \u201cOffer\u201d), copies of which are annexed to and filed with the Schedule TO
\nas Exhibits (a)(1)(A) and (a)(1)(B), respectively. <\/p>\n
All information contained in the Offer to Purchase (including Schedule I to the Offer to Purchase) and
\nthe accompanying Letter of Transmittal is hereby expressly incorporated herein by reference in response to Items 1 through 9 and Item 11 of the Schedule TO and is supplemented by the information specifically provided in this Amendment. This
\nAmendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment have the meanings given to such terms in the Offer to Purchase. <\/p>\n
Item\u20091 through 9; Item 11. <\/p>\n
The Offer to
\nPurchase and Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as follows: <\/p>\n
The second paragraph of the subsection entitled \u201cU.S. Antitrust Compliance\u201d in Section\u00a016 – \u201cCertain Legal Matters; Regulatory
\nApprovals\u201d is amended and supplemented by replacing the second paragraph with the following: <\/p>\n
\u201cUnder the HSR Act, the purchase of Shares in
\nthe Offer may not be completed until the expiration of a\u00a015-calendar-day\u00a0waiting period following the filing of certain required information and documentary
\nmaterial concerning the Offer (and the Merger) with the FTC and the Antitrust Division, unless the waiting period is earlier terminated by the FTC.\u00a0The waiting period under the HSR Act expired, effective July\u00a09, 2026, at 11:59 P.M. Eastern
\nTime. Accordingly, the HSR Condition to the Offer has been satisfied.\u201d <\/p>\n
\u00a0<\/p>\n
2 <\/p>\n","protected":false},"excerpt":{"rendered":"This Amendment No.\u00a03 (this \u201cAmendment\u201d) amends and supplements the Tender Offer Statement on Schedule TO (together with any…\n","protected":false},"author":2,"featured_media":67042,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[32221,20785,35753,35754,35755,28912,29104,32206,28952],"class_list":["post-80738","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-124-per-share","tag-gsk","tag-harmony-row","tag-hsr-clearance","tag-letter-of-transmittal","tag-nuvalent","tag-nuvl","tag-offer-to-purchase","tag-tender-offer"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116896817667401654","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/80738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=80738"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/80738\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/67042"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=80738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=80738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=80738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}